[go: up one dir, main page]

SG11202010645VA - Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disorders - Google Patents

Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disorders

Info

Publication number
SG11202010645VA
SG11202010645VA SG11202010645VA SG11202010645VA SG11202010645VA SG 11202010645V A SG11202010645V A SG 11202010645VA SG 11202010645V A SG11202010645V A SG 11202010645VA SG 11202010645V A SG11202010645V A SG 11202010645VA SG 11202010645V A SG11202010645V A SG 11202010645VA
Authority
SG
Singapore
Prior art keywords
lentivector
transduced
amelioration
lysosomal storage
storage disorders
Prior art date
Application number
SG11202010645VA
Inventor
Jeffrey Medin
Daniel Fowler
Murtaza Nagree
Tania Felizardo
Original Assignee
Medical College Wisconsin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical College Wisconsin Inc filed Critical Medical College Wisconsin Inc
Publication of SG11202010645VA publication Critical patent/SG11202010645VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • A61K38/443Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16041Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y101/00Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01205IMP dehydrogenase (1.1.1.205)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202010645VA 2018-04-27 2019-04-29 Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disorders SG11202010645VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862663786P 2018-04-27 2018-04-27
PCT/US2019/029639 WO2019210301A1 (en) 2018-04-27 2019-04-29 Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disorders

Publications (1)

Publication Number Publication Date
SG11202010645VA true SG11202010645VA (en) 2020-11-27

Family

ID=68295811

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010645VA SG11202010645VA (en) 2018-04-27 2019-04-29 Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disorders

Country Status (7)

Country Link
US (1) US12239693B2 (en)
EP (2) EP3784695B1 (en)
JP (1) JP2021522278A (en)
KR (1) KR20210005167A (en)
CN (1) CN112513072A (en)
SG (1) SG11202010645VA (en)
WO (1) WO2019210301A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020005341A1 (en) * 2018-06-29 2020-01-02 Icahn School Of Medicine At Mount Sinai Anc80 encoding sphingolipid-metabolizing proteins
CN115379863A (en) * 2020-04-14 2022-11-22 吉尼松公司 Carrier for treating acid ceramidase deficiency
CN118715316A (en) * 2022-10-08 2024-09-27 凌意(杭州)生物科技有限公司 Polynucleotides for treating GCase deficiency-related diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326007B1 (en) 1995-07-20 2001-12-04 The Regents Of The University Of California Attenuated lentivirus vectors expressing interferon
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
WO1998039463A2 (en) 1997-03-06 1998-09-11 Ueberla Klaus Lentivirus based vector and vector system
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
KR100556864B1 (en) 1997-05-13 2006-03-10 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Lentivirus-originated gene transfer vector
EP1003894A2 (en) 1997-07-18 2000-05-31 Chiron Corporation Lentiviral vectors
ES2337429T3 (en) 1999-10-11 2010-04-23 Institut Pasteur LENTIVIRAL VECTORS FOR THE PREPARATION OF IMMUNOTHERAPEUTIC COMPOSITIONS.
AU784988B2 (en) 1999-11-10 2006-08-17 Uab Research Foundation, The Lentiviral vector transduction of hematopoietic stem cells
US20020014242A1 (en) 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
US6627442B1 (en) 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
EP1446014A4 (en) 2001-10-01 2004-12-08 Univ Emory INTRODUCTION OF THE WLDS GENE FOR THE PREVENTION OF AXONAL DEGENERATION IN NEUROLOGICAL DISEASES
CA2462628C (en) 2001-10-02 2019-08-20 Institut Clayton De La Recherche Restricted expression lentiviral vectors
US8568709B2 (en) 2008-03-20 2013-10-29 University Health Network Thymidylate kinase fusions and uses thereof
KR20180108886A (en) 2010-03-23 2018-10-04 인트렉손 코포레이션 Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof
RU2013125923A (en) 2010-11-30 2015-01-10 Орфазиме Апс METHODS FOR INCREASING THE EXTRACELLULAR ACTIVITY OF HSP70
US9387236B2 (en) 2011-06-10 2016-07-12 Prothera Inc. Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
ES2632444T5 (en) * 2011-09-30 2022-03-02 Bluebird Bio Inc Compounds that enhance viral transduction
WO2013151672A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of oncology-related proteins and peptides
CA2930784C (en) 2013-11-22 2023-01-31 Cellectis Method for generating batches of allogeneic t cells with averaged potency
CN105828811B (en) * 2013-12-23 2022-04-08 Bcn肽类股份有限公司 Bicalutamide analogs or (S) -bicalutamide as exocytosis activating compounds for use in the treatment of lysosomal storage disorders or glycogen storage diseases
GB201407322D0 (en) 2014-04-25 2014-06-11 Ospedale San Raffaele Gene therapy
MX2016014773A (en) * 2014-05-14 2017-05-04 Esteve Labor Dr Adenoassociated virus vectors for the treatment of lysosomal storage disorders.
BR112017013300A2 (en) 2014-12-22 2018-02-27 Codexis Inc recombinant alpha galactosidase a and / or biologically active recombinant alpha galactosidase fragment, composition, recombinant polynucleotide sequence, expression vector, host cell, methods for producing a variant alpha galactosidase ae for treating and / or preventing symptoms of fabry, pharmaceutical composition, and, use of compositions.
WO2016183593A2 (en) 2015-05-14 2016-11-17 The Regents Of The University Of California Prenatal therapy
WO2017093464A1 (en) 2015-12-04 2017-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of amplifying a population of antigen-specific memory cd4+ t cells using artificial presenting cells expressing hla class ii molecules
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
JP7576293B2 (en) 2017-01-13 2024-10-31 アイカーン スクール オブ メディシン アット マウント サイナイ Compositions and methods for treating Farber disease
US11597917B2 (en) 2017-07-06 2023-03-07 The Medical College Of Wisconsin, Inc. In vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders
WO2019046815A1 (en) 2017-08-31 2019-03-07 Poseida Therapeutics, Inc. Transposon system and methods of use

Also Published As

Publication number Publication date
WO2019210301A1 (en) 2019-10-31
EP3784695B1 (en) 2023-08-09
EP3784695A4 (en) 2022-02-23
EP3784695A1 (en) 2021-03-03
US20210322472A1 (en) 2021-10-21
JP2021522278A (en) 2021-08-30
CN112513072A (en) 2021-03-16
KR20210005167A (en) 2021-01-13
US12239693B2 (en) 2025-03-04
EP4285921A2 (en) 2023-12-06
EP4285921A3 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
GB2575360B (en) Expandable sockets for use with portable media players
EP3332438B8 (en) Redox flow cell for the storage of electrical energy and use thereof
EP3200591A4 (en) Central memory t cells for adoptive t cell therapy
SG10202005898PA (en) Cell culture medium
EP3155620A4 (en) Memory cell and an array of memory cells
IL248538A0 (en) Adenoassociated virus vectors for the treatment of lysosomal storage disorders
EP3401981A4 (en) Electrode for energy storage devices
EP3134409A4 (en) Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
GB201715930D0 (en) Cell Culture Medium
EP3569697B8 (en) Stem cell therapy in endometrial pathologies
EP3145543A4 (en) Treatment of eosinophil or mast cell related disorders
SG11202010645VA (en) Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disorders
EP3380102A4 (en) Telomere extension and anti-inflammatory agents for cell regeneration
EP3122278A4 (en) Expandable catheter devices electrode array
EP3128003A4 (en) Medium for stem cell use
EP3765044A4 (en) Methods for treating non-cancerous disorders using hematopoietic cells
SG11202009770TA (en) Improving cell access procedure
EP3313386A4 (en) Methods and compositions for treating lysosomal storage disorders
EP3189155A4 (en) Methods relating to testing for lysosomal storage disorders
EP3178318A4 (en) Composition for promoting storage stability of stem cells
SG11202010878QA (en) Cell culture medium
GB201706854D0 (en) Therapeutic agents for lysosomal storage disorders
GB201702552D0 (en) Therapeutic agents for lysosomal storage disorders
EP3672590A4 (en) Methods for inducing hematopoietic stem cell specificity
GB201613828D0 (en) Therapeutic agents for lysosomal storage disorders